Fatty acid biosynthesis (and most biosynthetic reactions) requires NADPH to supply the reducing equivalents. Oxaloacetate is used to generate NADPH for biosynthesis in a two‐step sequence. The first step is the malate dehydrogenase reaction found in the TCA cycle. This reaction results in the formation of NAD from NADH (the NADH primarily comes from glycolysis). The malate formed is a substrate for the malic enzyme reaction, which makes pyruvate, CO 2 , and NADPH. Pyruvate is transported into the mitochondria where pyruvate carboxylase uses ATP energy to regenerate oxaloacetate.
Only 2-3 cannabinoids can be extracted from the plant in sufficient quantities to make the process economically viable.
Adams adds, "The biosynthesis process opens up access to drug discovery and therapeutic use of all 90+ cannabinoids, most of which occur in only trace amounts in the plant and cannot be extracted in an economical fashion."
InMed plans the following next steps for this promising technology:
Continue to generate new patents for the biosynthesis process leading to 'gateway' and 'downstream' cannabinoids
Optimize and validate system performance criteria with the pilot scale facility at University of British Columbia
Produce at pilot scale several downstream cannabinoids at pharmaceutical-grade purity
Scale-up the pilot production methods to commercial-size facility together with external vendors with extensive biosynthesis expertise
Optimize the commercial system to maximize quantities while minimizing time/cost
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.